modelR03CC02_1
Extends from Pharmacokinetic.Models.PK_2C.
Information
| name: | Salbutamol_1 | |
| ATC code: | R03CC02_1 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 4 | mg |
| volume of distribution: | 74 | L |
| clearance: | 13.5 | L/h |
| other parameters in model implementation | ||
Salbutamol (also known as albuterol) is a short-acting β2 adrenergic receptor agonist used for the rapid relief and prevention of bronchospasm in conditions such as asthma and COPD. It is globally approved and widely utilized in acute symptomatic management as well as prevention of exercise-induced bronchospasm.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers following intravenous administration.
References
Vet, NJ, et al., & de Hoog, M (2020). Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. Clinical pharmacokinetics 59(2) 257–264. DOI:10.1007/s40262-019-00811-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/31432470
Marques, L, & Vale, N (2024). Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients. Pharmaceutics 17(1) –. DOI:10.3390/pharmaceutics17010039 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39861686
Antoniu, S (2014). Bedoradrine for treating asthma and chronic obstructive pulmonary disease. Expert opinion on investigational drugs 23(8) 1149–1156. DOI:10.1517/13543784.2014.928284 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24938936
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)